These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 11916103

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
    Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, Sibutramine/Diabetes Clinical Study Group.
    Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 5. Sibutramine in overweight/obese hypertensive patients.
    Sharma AM.
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S20-3. PubMed ID: 11916102
    [Abstract] [Full Text] [Related]

  • 6. A review of the metabolic effects of sibutramine.
    Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS.
    Curr Med Res Opin; 2005 Mar; 21(3):457-68. PubMed ID: 15811215
    [Abstract] [Full Text] [Related]

  • 7. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
    Seimon RV, Espinoza D, Ivers L, Gebski V, Finer N, Legler UF, Sharma AM, James WP, Coutinho W, Caterson ID.
    Int J Obes (Lond); 2014 Sep; 38(9):1165-71. PubMed ID: 24406481
    [Abstract] [Full Text] [Related]

  • 8. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Pharm Pharm Sci; 2010 Sep; 13(3):378-90. PubMed ID: 21092710
    [Abstract] [Full Text] [Related]

  • 9. Sibutramine and the management of obesity.
    Poston WS, Foreyt JP.
    Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
    [Abstract] [Full Text] [Related]

  • 10. How does sibutramine work?
    Lean ME.
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S8-11. PubMed ID: 11916106
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological intervention: the antiobesity approach.
    Rissanen A.
    Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
    [Abstract] [Full Text] [Related]

  • 12. Obesity and type 2 diabetes: a conflict of interests?
    Williams G.
    Int J Obes Relat Metab Disord; 1999 Jun; 23 Suppl 7():S2-4. PubMed ID: 10455464
    [Abstract] [Full Text] [Related]

  • 13. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ, Ernest P.
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [Abstract] [Full Text] [Related]

  • 14. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK, Pekkarinen TA, Rissanen AM.
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
    [Abstract] [Full Text] [Related]

  • 15. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W, Goa KL.
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [Abstract] [Full Text] [Related]

  • 16. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects.
    Tankova T, Dakovska G, Lazarova M, Dakovska L, Kirilov G, Koev D.
    Acta Diabetol; 2004 Dec; 41(4):146-53. PubMed ID: 15660196
    [Abstract] [Full Text] [Related]

  • 17. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
    Van Gaal LF, Caterson ID, Coutinho W, Finer N, Maggioni AP, Sharma AM, Torp-Pedersen C, Ge H, Moran SA, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2010 Jan; 12(1):26-34. PubMed ID: 19758358
    [Abstract] [Full Text] [Related]

  • 18. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
    Serrano-Rios M, Melchionda N, Moreno-Carretero E, Spanish Investigators.
    Diabet Med; 2002 Feb; 19(2):119-24. PubMed ID: 11874427
    [Abstract] [Full Text] [Related]

  • 19. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [Abstract] [Full Text] [Related]

  • 20. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.
    Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C, SCOUT Executive Steering Committee, SCOUT investigators.
    Metabolism; 2009 Aug; 58(8):1109-15. PubMed ID: 19454355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.